NCT00156091View on ClinicalTrials.gov

Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)

PHASE3CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Schizophrenia
Interventions
DRUG

Olanzapine

5- 20 mg QD

DRUG

Asenapine

5 or 10 mg BID

OTHER

Placebo

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00156091 - Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784) | Biotech Hunter | Biotech Hunter